I see where you are coming from, if you listen to the questions from the webcast before you the most recent one all the analysts are focused on when they will be profitable. A lot of people on here including myself know that it isn’t about profitability, it’s about growth. As mentioned by DW on multiple occasions. They could be profitable when ever they pleased. Maybe the analysts don’t put much time into researching polynovo and just look purely at the numbers. But surely if you are a paid professional you would look at the product and the quality it has and the lives it has changed. Reducing debt from 5. Something million down to 1.2-1.3 during a tough first half due to covid. IMO (for whatever that is worth) that result doesn’t justify a 35% drop.. short sellers would have to have some responsibility in that surely? I don’t think it’s that people have their heads in the sand, I think it’s more so that they don’t believe that the analysts are looking at the right things about the company looking forward. Appreciate your posts bedger, you are just trying to explain both sides and I agree. Kick it also has a point, management don’t provide guidance, sales are still lumpy. Kick it came pretty damn close on his predictions so you have to show him the respect, also he has been following the shorts and providing great information the past few months. I understand that they might be worried about how fast they are trying to expand and if they can keep the costs under control to prevent a capital raise, but how long have they been waiting for a capital raise? Even during covid they still managed to survive without one. I think we are pretty safe
- Forums
- ASX - By Stock
- PNV
- Ann: FY22 Results Presentation
PNV
polynovo limited
Add to My Watchlist
2.09%
!
$1.22

Ann: FY22 Results Presentation, page-405
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.22 |
Change
0.025(2.09%) |
Mkt cap ! $842.8M |
Open | High | Low | Value | Volume |
$1.19 | $1.26 | $1.19 | $2.833M | 2.297M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16695 | $1.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.25 | 8000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 14807 | 1.220 |
1 | 82644 | 1.210 |
2 | 12200 | 1.200 |
3 | 123495 | 1.190 |
3 | 62102 | 1.185 |
Price($) | Vol. | No. |
---|---|---|
1.250 | 8000 | 1 |
1.265 | 201004 | 1 |
1.270 | 20000 | 1 |
1.280 | 3094 | 3 |
1.290 | 7717 | 3 |
Last trade - 16.11pm 04/07/2025 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online